You searched for "AMD"
Complement Factor H and Factor H-Like protein are expressed in human RPE cells
The role of inflammation in age-related macular degeneration (AMD) is well documented and the association of AMD with the inflammatory marker C-reactive protein (CRP) and members of the complement system underline the role of complements in AMD. Human complement factor...
HtrA1 enhances cell senescence
A genetic basis for age-related macular degeneration (AMD) has been greatly advanced in recent years. The role of identified pathways such as complement factor H in AMD has been widely investigated. However, the effect of other gene variants identified by...In conversation with Professor Usha Chakravarthy (2018)
Professor Chakravarthy popped by the Eye News stand at the 2018 Royal College of Ophthalmologists Annual Congress after her excellent Bowman Lecture. She gave us a summary of her presentation, which looked at how our understanding of AMD has changed...
Corneal crosslinking in pellucid marginal degeneration
Fourteen studies were included in this first review examining the use of corneal-crosslinking (CXL) to treat pellucid marginal degeneration (PMD). PMD is a bilateral, non-inflammatory corneal thinning disorder characterised by inferior peripheral corneal thinning 1-3mm from the limbus in the...My top five: Emerging alternatives to manage and treat nAMD
Wet (exudative or neovascular) age-related macular degeneration (AMD) is characterised by choroidal neovascularisation, in which new blood vessels from the choroid invade through Bruch’s membrane. These blood vessels proliferate beneath or through the retinal pigment epithelium (RPE), causing patients to...
Age-related macular degeneration
This review article offers an up to date review of the genetic and environmental risk factors associated with aetiology surrounding age-related macular degeneration (AMD). The article briefly describes the typical clinical presentation relating to early and late stages of the...
Four year outcomes of macular degeneration treated with ranibizumab
The authors report on a retrospective study of neovascular age-related macular degeneration (AMD) patients treated with a variable ranibizumab dosing regimen over a period of four years (from January 2007 to December 2011). A total of 600 treatment naïve eyes...Quantum technology first in eye disease detection
Scientists are working on a new device that could lead to a reduction in the number of people who go blind from age-related macular degeneration (AMD).
